NCT03817931 is a Phase 4 clinical trial of Anticholinergic in Overactive Bladder, sponsored by Baylor Research Institute.

Who is sponsoring NCT03817931?

NCT03817931 is sponsored by Baylor Research Institute.

What drugs are being tested in NCT03817931?

Interventions in NCT03817931: Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT).

What condition does NCT03817931 study?

NCT03817931 studies Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge.

Is NCT03817931 still recruiting?

NCT03817931 is currently completed. Last updated 2 February 2024.

Last reviewed 2024-02-02 · How we verify

NCT03817931

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Completed Phase 4 Last updated 2 February 2024

What this trial tests

Phase 4 trial testing Anticholinergic in Overactive Bladder in 12 participants. Completed in 26 February 2022.

Timeline

5 August 2019

Primary endpoint
2 February 2022

26 February 2022

Quick facts

Lead sponsor	Baylor Research Institute
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	12
Start date	5 August 2019
Primary completion	2 February 2022
Estimated completion	26 February 2022
Sites	2 locations across United States

Drugs / interventions tested

Anticholinergic — full drug profile →
Beta-3 Agonists, Adrenergic — full drug profile →
Functional magnetic resonance imaging (fMRI)
Rey Auditory Verbal Learning Test (RAVLT)

Conditions studied

Overactive Bladder — all drugs for Overactive Bladder →
Dementia — all drugs for Dementia →
Lower Urinary Tract Symptoms — all drugs for Lower Urinary Tract Symptoms →
Incontinence, Urge — all drugs for Incontinence, Urge →

Sponsor

Baylor Research Institute

Who can join

Adults 18 to 90, female only, with Overactive Bladder or Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Women presenting with overactive bladder symptoms will be randomized to one of 3 arms (anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing, functional MRI of the brain. Cognitive testing and functional MRI will be repeated after taking their double blinded intervention for 30 days.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults.
Stoniute A, Madhuvrata P, Still M, Barron-Millar E, et al · · 2023 · cited 12× · PMID 37160401 · DOI 10.1002/14651858.cd003781.pub3
Protocol for a multicenter randomized, double blind, controlled pilot trial of higher neural function in overactive bladder patients after anticholinergic, beta-3 adrenergic agonist, or placebo.
High RA, Danford JM, Shi Z, Karmonik C, et al · · 2020 · cited 4× · PMID 32728649 · DOI 10.1016/j.conctc.2020.100621
The effect of oral medications on fMRI brain activation: A randomized, double blind, controlled pilot trial of older women with overactive bladder.
High RA, Shi Z, Danford JM, Bird ET, et al · · 2023 · cited 2× · PMID 35925203 · DOI 10.1007/s00192-022-05300-8

Verify or expand the search:

Other trials of Anticholinergic

Trials testing the same drug.

NCT06301802 — Outcomes of Proactive Management of Children With Myelomeningocele · unknown
NCT03500146 — Sexual Function Trial of Overactive Bladder: Medication Versus PTNS · completed

Other recruiting trials for Overactive Bladder

Currently open trials in the same condition.

NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
NCT05895045 — Yoga for Treatment of Overactive Bladder in Pediatric Patients · NA · recruiting
NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting
NCT06935240 — Investigation of Effects of Electrical Stimulation in Women With Vaginal Laxity · NA · recruiting

Other Baylor Research Institute trials

Trials by the same sponsor.

NCT07467720 — Study to Evaluate the Clinical Utility of Radiation Exposure Reduction: Multi-site Rampart Guardian Peripheral Trial · NA · not yet recruiting
NCT07547878 — Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) · Phase 4 · not yet recruiting
NCT07460583 — ProActive Athlete Heart Program: Proposal for Cardiac Risk Screening in Former High-Intensity Athletes · NA · not yet recruiting
NCT07096544 — CALM Study: Cardiomems Assisted Lvad Management · NA · not yet recruiting
NCT07220395 — eHealth Literacy Intervention for Spanish Speaking Older Adults in the US · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03817931 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baylor Research Institute
Last refreshed: 2 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03817931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing